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Abstract
Aims/hypothesis Reduced occupancy of junctional occludin is a feature of human placental vessels in the diabetic milieu. However,
the functional consequence of this and whether this loss is due to differential expression of occludin splice variants is not known.
Our study aimed to investigate the effects of gestational diabetes mellitus (GDM), and its treatment, on endothelial junctional
integrity, gene and protein expression of occludin splice variants, and potential regulation of expression by microRNAs (miRNAs).
Methods Term placentas were obtained from normal pregnancies (n = 21), and pregnancies complicated by GDMwhere glucose
levels were controlled by diet (n = 11) or metformin (n = 6). Gene and microRNA (miRNA) expression were determined by
quantitative real-time PCR; protein expression by immunoblotting; endothelial junctional occupancy by fluorescence microsco-
py and systematic sampling; and paracellular leakage by perfusion of placental microvascular beds with 76 Mr dextran.
Transfection studies of miRNAs that target OCLN were performed in HUVECs, and the trans-endothelial electrical resistance
and tracer permeability of the HUVECs were measured.
Results All three predicted OCLN gene splice variants and two occludin protein isoforms were found in human placental
samples. In placental samples from diet-controlled GDM (d-GDM) pregnancies we found a lower percentage of conduit vessels
showing occludin immunoreactivity (12%, p < 0.01), decreased levels of the fully functional occludin isoform-A protein (29%),
and differential gene expression ofOCLN variant 2 (33% decrease), variant 3 (3.3-fold increase). These changes were not seen in
samples from the group with metformin-controlled GDM. In d-GDM placentas, increased numbers of conduit microvessels
demonstrated extravasation of 76 Mr dextran (2.0-fold). In d-GDM expression of one of the five potential miRNAs targeting
OCLN, miR-181a-5p, expression was 2.1-fold that in normal pregnancies. Experimental overexpression of miR-181a-5p in
HUVECs from normal pregnancies resulted in a highly significant downregulation of OCLN variant 1 (69%) and variant 2
(46%) gene expression, with decreased trans-endothelial resistance (78%) and increase in tracer permeability (1.3-fold).
Conclusions/interpretation Downregulationof expressionofOCLNvariant 2and the fully functional occludin isoform-Aprotein are a
feature of placentas in d-GDM pregnancies. These may be behind the loss of junctional occludin and the increased extravasation of
exogenous dextran observed. miR-181a-5p was in part responsible for the downregulation of occludin in placentas from d-GDM
pregnancies. InducedoverexpressionofmiR-181a-5pcompromised the integrityof theendothelial barrier.Ourdata suggest that, despite
goodglucose control, the adoptionof lifestyle changes aloneduring aGDMpregnancymaynot be enough toprevent an alteration in the
expression of occludin and the subsequent functional consequences in placentas and impaired vascular barrier function in offspring.
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VEGF Vascular endothelial growth factor
Introduction
Gestational diabetes mellitus (GDM) is defined as a carbohy-
drate intolerance resulting in any degree of hyperglycaemia first
recognised during the second or third trimester of pregnancy
[1]. GDM increases the risk of several negative consequences
for the mother and the infants, the most significant of which is a
predisposition to develop metabolic syndrome and type 2
diabetes [2, 3]. Placental pathophysiology in GDM also
includes increased insulin resistance, inflammation, increased
glucose uptake, alterations of glucose transporters and endothe-
lial dysfunction (including junctional integrity) [4, 5]. The latter
may affect fetal programming of adult cardiovascular disease.
Following the UK National Institute for Health and Care
Excellence (NICE) guidelines, all women diagnosed with
diabetes are advised to adjust their diet and adopt a physical
exercise routine if they are planning a pregnancy or are preg-
nant [6]. Lifestyle changes are sufficient to control
hyperglycaemia in 80–90% of women with GDM [7]. If a diet
change is insufficient, metformin or insulin are used [6].
The placenta, a fetal end organ, forms a semi-permeable
barrier between mother and fetus. It is composed of numerous
chorionic villi containing fetal exchange capillaries, which
pick up nutrients, and conduit microvessels, which transport
solutes back to the fetus via the chorionic plate venous
network and single umbilical vein [8]. The villous outer lining
is a single multinucleated layer of syncytiotrophoblast, which
is in direct contact with maternal blood. The haemodynamics
here will influence solute uptake and oxygenation [8].
Hydrophilic solutes have to cross both the syncytiotrophoblast
and the endothelium to reach the fetal blood [9]. The endothe-
lial layer acts as a barrier in series by containing well-defined
junctions (adherens and tight junctions). Disruption here leads
to reduced junctional restrictiveness, altered cleft dimensions
[10], increased solute transit time and paracellular vascular
leaks [11, 12], all impacting on optimal nutrient delivery to
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the developing fetus and impaired placental barrier function.
In the blood–brain barrier, tight junction disruption has been
shown to lead to changes in the efflux/influx of hydrophilic
solutes [13]. Disruption of junctions by histamine can increase
arterial flow and permeability of venules in the mouse ear
[14]. Similar mechanisms may be at play in the human
placenta.
A perfusion study using freshly delivered term placenta
from pregnancies complicated with type 1 diabetes reported
an increase in vascular leakage in all vessels of the microvas-
cular bed [15]. This was correlated with perturbations of junc-
tional proteins, phosphorylation of VE-cadherin and increased
vascular endothelial growth factor (VEGF) protein expression
[15]. Likewise, placentas from pregnancies complicated by
GDM have shown loss of junctional proteins [5, 16].
However, studies into the genetic or epigenetic regulation of
these transmembrane junctional proteins were not performed.
Occludin is a tight junctional strand protein that interacts
with scaffolding proteins in the zonula occludens to adjoin
cell–cell overlap of paracellular clefts andmaintain the integrity
of tight junctions. Loss of occludin and disrupted tight junc-
tions are a feature of diabetic retinopathy [17], and this feature
has also been reported in placental vessels in pregnancies
complicated with GDM [5]. Whether differential expression
of splice variants of the gene encoding occludin (OCLN) is
behind these changes requires investigation. The human
OCLN gene includes nine exons (Fig. 1a) and alternative splic-
ing produces different mRNAs [18]. The NCBI database
reports three predicted splice variants (Fig. 1b): OCLN variant
1 (NM_002538.3), variant 2 (NM_001205254.1) and variant 3
(NM_001205255.1). Differences in exon conformation and
promoter regions lead to the translation of two different protein
isoforms (Fig. 1c): occludin isoform-A (NP_002529.1) and
isoform-B (NP_001192184.1). OCLN variant 1 and variant 2
translate into occludin isoform-A (~60 kDa), a complete and
functional protein that can localise to the membranes of tight
junctions and participate in homophilic binding. OCLN variant
3 translates into a truncated cytoplasmic occludin, known as
isoform-B (~30 kDa). The function of isoform-B has not been
described; however, a study using Madin-Darby Canine
Kidney (MDCK) cells expressing chimeric occludin deter-
mined that a variant that lacks extracellular loops but presents
the COOH-terminal cytoplasmic domain results in intracellular
vesicular accumulation of all the scaffold of tight junction
proteins [19].
Occludin expression can be epigenetically regulated. For
example, the microRNAs (miRNAs) miR-18a-5p [20, 21],
miR-181a-5p [22], miR-21-3p [23], miR-122-5p [24, 25],
and miR-340-5p (DIANA database; http://diana.imis.athena-
innovation.gr/DianaTools/index.php) have been reported to
be expressed in human placenta and to target OCLN
expression in different tissues. The relationship between
each miRNA, human placenta, OCLN expression and GDM
has not previously been analysed.
The aim of this study was to determine the effects of GDM
on the integrity of the feto-placental vessels and the expression
of occludin. We hypothesised that the type of treatment used
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Fig. 1 Schematic representation
of human occludin mRNA and
protein products. (a) Gene
structure of human occludin
includes nine exons. Alternative
splicing generates three variants.
Alternative transcriptional start
sites (TSS1 and TSS2, black
arrows) and translational start
sites (ATG1 and ATG2, orange
arrows) in exons 1, 2 and 4 are
indicated. The stop codon within
exon 9 is also indicated (TGA, red
arrow). (b) Three mRNA variants
are generated. ATG1 forms
OCLN variants 1 and 2, each of
these two variants has a different
transcriptional start site. ATG2
generates OCLN variant 3. (c)
OCLN variant 1 and 2 translate
into occludin isoform-A; a fully
functional, membrane protein.
OCLN variant 3 translates into
occludin isoform-B, a truncated,
cytoplasmic protein
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influences the level to which the placental vasculature is
affected.
Methods
Study population Pregnant women, with singleton pregnan-
cies, were recruited at the Queen’s Medical Centre,
Nottingham University Hospitals NHS Trust, UK. This study
had the approval of the East Midland Nottingham 2 – Health
Research Authority (Ref: OG010101). It was carried out in
accordance with The Code of Ethics of the World Medical
Association (Declaration of Helsinki).
Term placentas (N = 38; >37 weeks’ gestation) from elec-
tive Caesarean sections (C-sections) were collected after
informed consent. We chose to collect placentas only from
C-sections in order to minimise the effects of post-
parturition hypoxia and ischaemia and obtain placentas that
had not received labour signals. For protein localisation,
protein expression and gene expression analysis, placental
samples were obtained from three groups: normal pregnancies
(n = 9), pregnancies complicated with GDM treated by a
change of diet (n = 7) (d-GDM) or by metformin (n = 6) (m-
GDM) (Table 1). For tracer leakage analysis, term placentas
were collected from normal pregnancies (n = 4) and d-GDM
pregnancies (n = 4) (Table 2). Transfection studies, trans-
endothelial resistance and permeability experiments were
done with HUVECs isolated from normal pregnancies (n = 8).
Women in all groups were of similar age, had no vascular
complications, pre-eclampsia or hypertension, were non-
smokers and were not taking any other medications.
Tissue preparation and sampling Placentas and umbilical
cords were taken immediately after delivery. Chorionic
villous biopsies were taken from four quadrants, midway
between the umbilical cord insertion and the placental rim.
For immunostaining, fresh tissue was fixed in 1% (wt/vol.)
paraformaldehyde (PFA), frozen in nitrogen-cooled
isopentane and stored at −80°C. For protein extraction, tissue
was snap-frozen and stored at −80°C. For RNA isolation,
tissue was placed in RNAlater solution (Sigma-Aldrich,
USA) and stored at −20°C. For tracer leakage analysis,
placentas were immediately processed as described below.
Systematic random sampling of junctional occludin in vascu-
lar profilesAn indirect immunofluorescence method was used
[26]. Briefly, frozen placental sections were permeabilised
with acetone and 0.1%Triton X-100, blocked with 5% normal
human serum, and incubated with primary antibodies for
occludin (2.5 μg/ml; rabbit polyclonal; catalogue no. 71-
1500, Thermo Fisher, USA) and the endothelial marker plate-
let endothelial cell adhesion molecule 1 (PECAM-1)
(2.5 μg/ml; mouse monoclonal; catalogue no. BBA7, R&D
Systems, UK). Sections were washed thoroughly and incubat-
ed with the appropriate secondary antibodies: FITC-
conjugated anti-rabbit (10 μg/ml; catalogue no. F0382,
Sigma-Aldrich) and tetramethylrhodamine isothiocyanate
Table 1 Clinical characteristics
of the study population that had









Maternal age, years 34.67 (6.04) 30.57 (6.78) 31.83 (4.71) 0.390
Maternal BMI, kg/m2 25.71 (4.27) 29.20 (7.54) 32.38 (6.89) 0.145
Gestational age at delivery, weeks 38.69 (1.18) 39.17 (0.26) 39.40 (0.37) 0.236
HbA1c, mmol/mol – 37.44 (3.99) 36.60 (2.97) 0.848
HbA1c, % – 5.57 (0.36) 5.60 (0.34) 0.924
Placental weight, g 674.4 (108.9) 674.4 (119.4) 644.2 (98.4) 0.848
Baby weight, kg 3.49 (0.37) 3.54 (0.69) 3.62 (0.71) 0.924























Data are presented as mean (SD); p value calculated by one-way ANOVA
[F], neonatal sex female; [M], neonatal sex male
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(TRITC)-conjugated anti-mouse (10 μg/ml; catalogue no.
T5393, Sigma-Aldrich). All antibodies were diluted in 0.1%
(wt/vol.) BSA in 0.1 mol/l PBS.
Immunoreactivity in the sections was visualised (blind)
using a Nikon microscope (LaboPhot-2, Nikon Instruments,
UK). A systematic random sampling of fields of view was
adopted and micrographs acquired. The number of vascular
profiles showing immunoreactivity to occludin and PECAM-
1 was counted using the unbiased ‘forbidden line’ counting
principle [27]. Nomore than 150 vascular profiles were count-
ed for each placenta to maintain sampling efficiency.
Protein isolation and western blotting Placental tissue was
homogenised in protein lysis buffer (50 mmol/l Tris pH 8.0,
150 mmol/l NaCl, 0.5% deoxycholate, 1% Triton X-100,
0.1% [wt/vol.] sodium dodecyl sulphate [SDS]) plus
2 mmol/l phenylmethylsulfonyl fluoride (PMSF), a protease
(Roche, Germany) and phosphatase inhibitors cocktails
(Sigma-Aldrich). Protein concentration was measured using
the DC Protein Assay (Bio-Rad, USA).
Total protein (40 μg) was separated on a 4–20% SDS-
PAGE gel (Bio-Rad). Nitrocellulose membranes were incu-
bated with primary antibodies: polyclonal rabbit anti-occludin
(0.5 μg/ml; catalogue no. 71-1500, Thermo Fisher), and
monoclonal mouse anti-β-actin (7 μg/ml; catalogue no.
A531, Sigma-Aldrich). Secondary antibodies: goat anti-
rabbit (catalogue no. 926-32211, LI-COR, Germany), and
goat anti-mouse (catalogue no. 925-68070, LI-COR) diluted
to 0.1 μg/ml. Membranes were scanned with an Odyssey
Infrared Imaging System 3.0 (LI-COR). Quantification of
bands was performed with ImageJ Software Version 2.0
[28]. Fluorescence intensity of occludin bands was normalised
to their respective loading control. All antibodies were diluted
in blocking buffer (5% [wt/vol.] milk (in 1× Tris-Buffered
Saline, 0.1% Tween 20 detergent).
A similar protocol was used for VEGF-Awith minor modi-
fications: 20 mg of total protein and primary antibody poly-
clonal rabbit anti-VEGF-A (3.6 μg/ml; catalogue no.
ab183100, Abcam).
RNA isolation and qPCR Total RNA was extracted using TRI
Reagent (Sigma-Aldrich) and a TissueLyser LT (Qiagen,
Australia) homogeniser. RNA quantity and quality were
assessed using the NanoDrop spectrophotometer ND-2000
(Thermo Fisher).
Five μg of total RNA were reverse transcribed using
SuperScript III Reverse Transcriptase (Invitrogen, USA) and
random primers (Promega, USA). Quantitative real-time PCR
(qPCR) reactions were performed in triplicate with SYBR
Green JumpStart Taq ReadyMix (Sigma-Aldrich), and detec-
tion was performed using the Rotor-Gene 6000 cycler
(Corbett Research, Mortlake, NSW, Australia). The thermal
profile included 95°C for 10 min, 40 cycles of 95°C for 15 s,
annealing temperature (specific of each primer) for 30 s, and
72°C for 40 s (Table 3). Gene expression was normalised to a
geometric average of three reference genes (YWHAZ, TBP,
SDHA) [29]. The relative expression changes were deter-
mined using the relative quantification (2−ΔΔCt ) method [30].
Placental perfusion A well-established dual-perfusion proce-
dure was employed [9, 11, 12, 27]. Briefly, immediately after
delivery by C-section, the placenta was transferred to a 37°C
chamber with the umbilical cord kept clamped to prevent loss
of blood and collapse of feto-placental vessels.Within 20min,
a chorionic vein and an artery supplying a chosen cotyledon
were cannulated to establish the fetal circulation. Fetal arterial
inflow and venous outflow was measured to ensure they were
the same. Once venous outflow showed clear blood-free
perfusate (several minutes), the placenta was inverted and
the cotyledon clamped in a Perspex chamber to isolate it from
Table 2 Clinical characteristics
of the study population that had







Maternal age, years 30.75 (3.76) 32.00 (7.53) 0.777
Maternal BMI, kg/m2 27.00 (2.83) 29.15 (3.37) 0.366
Gestational age at delivery, weeks 38.25 (0.96) 37.50 (1.30) 0.387
HbA1c, mmol/mol 38.50 (3.51)
HbA1c, % 5.68 (0.32)
Placental weight, g 817.8 (125.1) 898.5 (199.7) 0.519
Baby weight, kg 4.04 (0.49) 4.15 (0.31) 0.706









Data are presented as mean (SD); p value calculated by one-way ANOVA
[F], neonatal sex female; [M], neonatal sex male
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the rest of the placenta. The independent maternal circulation
was simulated by inserting five nasogastric tubes (equally
spaced, one per lobule) into the intervillous space through
the basal plate of the cotyledon and drained through an exit
tube in the chamber. Fetal and maternal circulations were
connected to peristaltic pumps providing a constant flow of
20 ml/min to the maternal circulation and a 5 ml/min flow to
the fetal circulation. Maternal and fetal perfusion pressures
were monitored continually by placing pressure transducers
just prior to arterial inflows of both circuits. A maternal blood
pressure of 18–20 mmHg and a fetal blood pressure of 40–
80 mmHg was accepted as normal. Increases above these
ranges led to abandonment of the experiment (one in five
failure rate). Flow rates and perfusion pressures were
visualised continually with ML866/P PowerLab 4/30 record-
ing unit and LabChart Pro software (ADInstruments, UK).
A 20 min open circuit equilibration period was performed
to reverse any post-parturition hypoxic changes [9]. During
this period, both circuits were irrigated with oxygenated
Medium 199 (Sigma-Aldrich), with added sodium bicarbon-
ate (2.2 g/l), albumin (5 g/l), high-molecular-weight dextran
(2000 Mr; 8 g/l) and heparin (5000 IU/l) (final pH 7.2–7.4).
After equilibration, fetal oxygenation was stopped, 76 Mr
dextran conjugated with TRITC (1 mg/ml; Sigma-Aldrich)
was added as a bolus into the closed fetal circulation for
10 min. The maternal circuit remained open, oxygenated and
tracer free. Finally, 1% (wt/vol.) PFA was introduced into the
fetal circuit, the clamped Perspex chamber was removed to
prevent bulk flow and the cotyledon perfusion fixed for
30 min. The cotyledon was excised, weighed (~50 g) and
vertical slices (basal plate to chorionic plate) from fixed,
blanched lobules only were taken for a further immersion
fixation (1 h). Biopsies (villous trees) were frozen in
nitrogen-cooled isopentane and stored. Cryosections were
obtained, PECAM-1 detected by immunocytochemistry, and
micrographs acquired by systematic random sampling of
fields of view.
Tracer leakage sampling The vascular profiles displaying trac-
er leakage (hotspots) were counted (blinded) using unbiased
‘forbidden line’ counting principle [12, 15, 27]. To maintain
efficiency, between 100 and 200 vessels were counted in each
placenta from each group. The number of vessels with
hotspots (in terminal, intermediate and stem villi) was subse-
quently expressed as a percentage of total vessels counted (all
vessels in the field of view). The percentages of conduit
vessels in stem and intermediate villi from normal and d-
GDM groups were analysed for this study.
Quantification of microRNA expression Total RNA (5 ng) was
reverse transcribed using a miRCURYLNATMUniversal RT
microRNA PCR Kit (Exiqon, Denmark) per manufacturer’s
instructions. miRNAs that target OCLN expression were
selected based on literature and a bioinformatics search using
three databases: miRBase (www.mirbase.org), miRTarBase
(http://mirtarbase.mbc.nctu.edu.tw) and DIANA (http://
diana.imis.athena-innovation.gr/DianaTools/index.php). Five
miRNAs were selected: miR-18a-5p, miR-21-3p, miR-122-
5p, miR181a-5p and miR-340-5p. Exiqon primers were used
for amplification (catalogue nos YP00204207, YP00204302,
YP00205664, YP00206081 and YP00206068, respectively).
qPCRs were conducted in triplicate using ExiLENT SYBR
Green master mix (Exiqon). Detection was performed using
the Rotor-Gene 6000 cycler; 95°C for 10 min, followed by
40 cycles of 95°C for 10 s, and 60°C for 1 min. Samples were
diluted 1:80 before qPCR and 4 μl of the diluted samples were
used in 10 μl reactions. U6 spliceosomal RNA gene was used
as an internal control (catalogue no. YP00203907).
Table 3 Primer sequences










OCLN variant 1 F: 5′- TGAATTGGTCACCGAGGGAG-3′
R: 5′- TAAACCAATCTGCTGCGTCCTA-3′
600 1:8 60a
OCLN variant 2 F: 5′- GGCGAGCGGATTGGTTTAT-3′
R: 5′- AAGGAGGTGGACTTTCAAGAGG-3′
600 1:64 58a
OCLN variant 3 F: 5′-CCTTACAGGCCTGATGAATTGC-3′
R: 5′-TGTCCATCTTTCTTCGAGTTTTC-3′
F 300 / R 800 1:8 62a
VEGF-A F: 5′- ATCTTCAAGCCATCCTGTGTGC-3′
R: 5′- TATGTGCTGGCCTTGGTGAG-3′
700 1:8 60b
a 1 mmol/l betaine was needed for the specificity of the qPCR reaction
F, forward; R, reverse
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Transfection of HUVECs with miRNA HUVECs were isolated
from normal pregnancies (n = 4) following a standardised proto-
col [31]. HUVECs were used for transfection of miR-181a-5p
mimic between passages 2 or 3. Optimisation of transfectionwas
done following manufacturer’s instructions (Dharmacon
Research, USA). Briefly, HUVECs were seeded into 12 well
plates at ~2.0  105 cells/well in transcription medium (TM20,
which is antibiotic-free M199 [catalogue no. 12340030, Thermo
Fisher] with 20% FCS) and cultured overnight at 37°C in a
humidified incubator with 5% CO2 in air. Each sample was
treated under four conditions (n = 3 per condition, per sample):
untreated control (TM20); transfection control (TM20 + trans-
fection reagent); negative control (TM20+ transfection reagent +
negative control mimic); miR-181a-5p transfection (TM20 +
transfection reagent + miR-181a-5p mimic). Each reaction need-
ed 0.75% DharmaFECT-1 transfection reagent (T-2001-01,
Dharmacon), 15 nmol/l miRIDIAN miR-181a-5p mimic
(C-300552-05-0005, Dharmacon), or 15 nmol/l miRIDIAN
mimic negative control (CN-001000-01-05, Dharmacon). Cells
were cultured for 24 h and the transfectionmediumwas replaced
with fresh TM20 for a further 24 h incubation. Finally, cells were
washed and TRI Reagent was used to isolate RNA.
HUVEC permeability assays For assessment of trans-
endothelial electrical resistance (TEER), HUVECs isolated
from normal pregnancies (n = 4) were seeded in triplicate onto
gelatine-coated 12 transwell inserts (catalogue no. CLS3493,
Corning, USA). TEER was measured in triplicate before
transfection and every 24 h for the next 3 days using an
EVOM volt meter (World Precision Instruments, UK).
TEER values were subtracted from blank TEER values
(inserts without cells) and multiplied by the surface area of
the transwell.
For tracer leakage, an aliquot of the same HUVECs used for
TEER (n = 4) was seeded under similar conditions. After
HUVECs were transfected (48 h), medium was replaced with
phenol-free M199 (catalogue no. 11043023, Thermo Fisher),
apical 0.5 ml, basal 1.5 ml, ensuring same level in inner and
outer well. FITC-conjugated dextran (molecular weight
76,000; 1 mg/ml; Thermo Fisher) was added to the apical cham-
ber. Fifty microlitres of medium from the basal chamber were
collected every 30 min for 2 h; the volume taken was replaced to
ensure hydrostatic pressure remained balanced after each sample
collection. Tracer leakage was measured by a fluorescence
microplate reader (Labtechnologies FLUOstar Galaxy
Microplate Reader, UK) at an emission/excitation wavelength
of 485/520 nm. The concentration of tracer in each sample was
calculated via linear regression of a standard curve. Absolute
permeability (cm/s) was calculated as the ratio of the tracer leak-
age to the concentration gradient as follows [32]:
P ¼ C tð Þ – C t0ð Þ½   V
A t  C0
Where C(t) and C(t0) are the tracer concentrations (μg/ml)
at 120 min and 0 min, respectively, estimated by linear regres-
sion; V is the volume in the lower compartment (1.5 cm3); A is
the surface area of the transwell membrane (1.1 cm2); t is the
duration of the flux (7200 s); andC0 is the initial concentration
of the tracer on the apical side (1000 μg/ml).
Statistical analysis Data are expressed as mean ± SEM. Data
were tested for normality of the distribution by the
D’Agostino–Pearson test with a confidence interval of 95%.
Study population, protein localisation, protein expression,
placental perfusion, miRNA expression, TEER and HUVEC
tracer leakage were normally distributed. Statistical compari-
sons between two groups were performed by independent
samples t test, and among the three groups by one-way
ANOVA. Results from gene expression were not normally
distributed. Statistical comparison here were performed by
Mann–Whitney U test and Kruskal–Wallis test. Pearson’s
and Spearman’s rank correlation coefficients were used
depending on the normality distribution of the data. All statis-
tics were calculated and graphs plotted with GraphPad Prism
6.0 (GraphPad Software, USA); p < 0.05 was considered
statistically significant.
Results
Comparison of maternal characteristics Comparisons of clin-
ical details between each group, samples used for gene and
protein expression (Table 1) and for placental vascular perme-
ability (Table 2), showed no significant difference in maternal
age, BMI, gestational age at delivery, placental weight, or
baby weight (p > 0.05). The HbA1c from all women with
GDM showed that glucose levels were under control with
both diet and metformin approaches (HbA1c <39.0 mmol/
mol or <5.7%).
Birthweight centiles revealed that some babies were above
the 95th centile, and therefore classified as large for gestation-
al age (LGA) [33] in both the normal and GDM groups.
However, no significant differences were found between
groups. There were no correlations between birthweight
centiles and occludin protein or gene expression (Pearson’s
correlation coefficient p > 0.01). In the perfused placentas,
no significant correlation was detected (Spearman’s rank
correlation coefficient; p > 0.01) between vascular leakage
and selected variables, which included maternal HbA1c,
birthweight, birthweight centile and placental weight.
Lower percentage of junctional occludin-positive vessels in d-
GDM The percentage of PECAM-1-positive vascular
profiles in stem and intermediate villi showing junctional
localisation of occludin were significantly different among
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the groups (p = 0.015) (Fig. 2). In terms of the proportion
of occludin-positive vessels, the percentage value was 12%
lower in d-GDM samples than in normal samples (p =
0.005) and 10% lower in d-GDM samples than m-GDM
samples (p = 0.049). There was no difference in the
percentage of occludin-positive vessels between the normal
and m-GDM samples. Figure 3 shows localisation of
occludin and PECAM-1 in conduit vessels from normal
and GDM placental samples.
Occludin protein expression is affected in d-GDM Two
occludin protein isoforms were detected in human placental
samples (Fig. 4a). Occludin isoform-A expression was 29%
lower in placental samples from d-GDM pregnancies
compared with samples from normal pregnancies
(p = 0.040) (Fig. 4b). Occludin isoform-B expression was
similar among the groups (p = 0.938) (Fig. 4c). In placental
samples from the m-GDM pregnancies, protein expression of
these occludin isoforms was similar to that in samples from
normal pregnancies.
OCLN gene expression is affected in d-GDM All three predict-
ed OCLN splice variants were found in placental samples;
OCLN variant 2 represents 67% of total OCLN gene expres-
sion in placental samples from normal pregnancies (Fig. 5a).
OCLN variant 2 expression was 33% lower in d-GDM
samples than in normal placental samples (p = 0.016) (Fig.
5c). In the d-GDM samples, OCLN variant 3 gene expression
was 3.3-fold that in normal placental samples (p = 0.020)
(Fig. 5d). OCLN variant 1 expression was similar in placental
samples among the groups (p = 0.194) (Fig. 5b). Gene expres-
sion of these OCLN splice variants in placental samples from
the m-GDM pregnancies was similar to that in samples from
normal pregnancies.
Placental vascular permeability is compromised in d-GDM In
placentas from d-GDM pregnancies the percentage of placen-
tal conduit vessels (residing in intermediate and stem villi)
associated with tracer hotspots was 2.0-fold that in placentas
from the normal pregnancy group (p = 0.009) (Fig. 6). In the
latter, the number of vessels associated with leaks was sparse
(Fig. 6a, b), corresponding to 10.18% of the total observed
vessels (Fig. 6f). Moreover, the leaks (number of associated
hotspots) were discreet. Placental vessels from d-GDM preg-
nancies showed numerous (>2) hotspots per vessel (Fig. 6c–e)
and 19.92% of the total observed vessels showed hotspots
(Fig. 6f).
Increased miR-181a-5p expression in d-GDM placental
samples From the five miRNAs screened, three were found
in the human placenta: miR-18a-5p, miR-21-3p, and miR-
181a-5p (Fig. 7). The expression of miR-18a-5p (p = 0.293)
(Fig. 7a) and miR-21-3p (p = 0.780) (Fig. 7b) was not differ-
ent among the groups. In placental samples from d-GDM
pregnancies, miR-181a-5p expression was 2.0-fold that in
placental samples from normal samples (p = 0.043) (Fig.
7c). In placental samples from m-GDM pregnancies, expres-
sion of these miRNAswas not significantly different from that
in samples from normal pregnancies.
Overexpression of miR-181a-5p downregulates OCLN variant
1 and 2 expression in HUVECs Overexpression of miR-181a-
5p was confirmed by comparing its expression under control
conditions with that in miR-181a-5p mimic transfection
conditions (p = 0.007) (Fig. 8a). The expression of OCLN
variant 1 was stable among the three control conditions
(p > 0.05), and 69% lower in miR-181a-5p mimic transfection
compared with untreated control (p = 0.010), transfection
control (p = 0.004) and negative control (p < 0.001) (Fig.
8b). Likewise, OCLN variant 2 expression was stable among
the three control conditions (p > 0.05), and 46% lower in miR-
181a-5p mimic transfection compared with untreated
(p = 0.009) and transfection control (p = 0.018) (Fig. 8c).
OCLN variant 3 expression was stable between conditions
(p = 0.509) (Fig. 8d).
Overexpression of miR-181a-5p decreased endothelial barrier
integrity and increased permeability in HUVECs TEER was
measured to evaluate whether the overexpression of miR-
181a-5p would affect endothelial barrier integrity (Fig. 9a).
During the different timepoints, resistance was stable among
the controls (p > 0.05). A reduction of resistance was seen
48 h after transfection, HUVECs overexpressing miR-181a-
5p showed 35% lower resistance than controls (p < 0.05). This
reduction was increased 72 h after transfection, showing 78%
lower resistance than controls (p < 0.001).
Tracer leakage was measured to evaluate permeability in




















Fig. 2 Reduced percentage of occludin-positive vessels in d-GDM preg-
nancies. Placental samples were taken from normal pregnancies (n = 9),
and pregnancies complicated with d-GDM (n = 7) or m-GDM (n = 6) and
the endothelial marker PECAM-1 and occludin were immunolabelled
prior to systematic counts. The graph shows the percentage of vessels
with junctional occludin in the samples from the three groups. Data are
presented as mean ± SEM; missing data correspond to outliers. One-way
ANOVA between groups (F(2, 15) = 5.57, p = 0.015); *p < 0.05,
**p < 0.01 by post hoc unpaired t test
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experiments, permeability was stable among the controls
(p > 0.05). In HUVECs overexpressing miR-181a-5p perme-
ability was 1.3-fold that in the untreated control HUVECS
(p = 0.02) (Fig. 9b).
VEGF-A protein expression is affected in d-GDM samples
VEGF-A protein expression was 26% lower in placental
samples from d-GDM pregnancies than in placental
samples from normal pregnancies (p = 0.044; Fig.
10a). Placental samples from the m-GDM pregnancies
showed stable VEGF-A protein expression compared
with samples from normal pregnancies. Total VEGF-A
gene expression was similar between groups (p = 0.370)
(Fig. 10b).
Discussion
This study is the first to show the presence of the three predict-
ed OCLN splice variants and their two protein isoforms in
human placenta. Our data from the d-GDM group suggests
that well-controlled glucose may not be enough to protect
against alterations to the OCLN gene and occludin protein
expression or junctional localisation. Furthermore, we demon-
strate that conduit placental microvessels of placental samples
from d-GDM pregnancies have a higher percentage of leaky
vessels than those in placental samples from normal pregnan-
cies. Interestingly, occludin expression and junctional
localisation were similar between placental samples from m-
GDM pregnancies and normal pregnancies, and so it is
Fig. 3 Representative
micrographs showing occludin
and PECAM-1 localisation in
conduit vessels from normal and
GDM placentas. Placental
samples were taken from normal
pregnancies (n = 9), and d-GDM
pregnancies (n = 7) or m-GDM
pregnancies (n = 6). (a, b) Full
junctional occupancy of occludin
(FITC) (a) and PECAM-1
(TRITC) (b) can be seen in all
vascular profiles in intermediate
villi (iv) from normal
pregnancies. (c, d) Micrographs
showing a similar full occupancy
of occludin (c) and PECAM-1 (d)
in intermediate villous vessels
from the metformin-treated study
group. Figure 3c was taken at a
different camera setting (higher
gain), to ensure vascular
localisation could be seen. (e–h)
Micrographs from diet-controlled
GDM placentas showing loss of
occludin staining (e) from
numerous PECAM-1-positive
vascular profiles in intermediate
villus (f). (g, h) A stem villus (sv)
showing occludin
immunostaining with TRITC–
conjugated anti-rabbit IgG (g) and
anti-PECAM-1 immunoreactivity
with FITC-conjugated anti-mouse
IgG (h). The arrow points to a
large vessel with a reduced
number of paracellular clefts
showing occludin. Note the
presence of occludin in the
trophoblast layer in all study
groups. Scale bar, 50 μm
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tempting to speculate that metformin may help prevent alter-
ations in occludin expression. Expression of miR-181a-5p
was found to be significantly higher in placentas from d-
GDM pregnancies. Overexpression of miR-181a-5p in
HUVECs from normal pregnancies led to a downregulation
of OCLN gene expression and reduced endothelial barrier
integrity. It is therefore possible that the downregulation of
OCLN expression in placentas from d-GDM pregnancies
may have been epigenetically controlled, in part, by miR-
181a-5p expression.
Analyses of junctional localisation of occludin revealed a
12% decrease in occludin-positive vessels in the d-GDM
samples. This is in agreement with findings from a previous
study showing reduced junctional occludin in placental vascu-
lature in insulin-controlled GDM pregnancies [5]. In the pres-
ent study, no changes were found in placental samples from
the m-GDM group. This marked difference between the two
GDM groups reinforces our hypothesis that the type of treat-
ment used to control glucose levels in pregnancies complicat-
ed with GDM is an important factor to consider when
analysing data. The loss of occludin from tight junction
domains may be a consequence of inflammation. Indeed,
phosphorylation of junctional adhesion molecules by VEGF-
A, resulting in loss of anchorage and internalisation, is a well-
established acute response [12, 15, 17, 27]. In our study we
did not see increased expression of VEGF-A protein, but,
rather, a decrease in the d-GDM placentas. Whether this was
due to a reduction in the expression of VEGF-A165a or the
anti-permeability VEGF-A165b splice variant remains to be
shown. We have previously shown that perfusion with
VEGF-A165a results in increased albumin leakage from








































































































































Fig. 5 Differential gene
expression of OCLN in human
placental tissue from d-GDM
pregnancies. Placental samples
were taken from normal
pregnancies (n = 9), and d-GDM
(n = 7) or m-GDM (n = 6)
pregnancies. (a) Total OCLN
gene expression is produced by
three OCLN splice variants (var)
in human placenta from normal
pregnancies. (b–d) Gene
expression ofOCLN variant 1 (b),
OCLN variant 2 (c) and OCLN
variant 3 (d) in the three groups.
Data are presented as mean ±
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Fig. 4 Reduced occludin isoform-A protein expression in human placen-
tal tissue from d-GDM pregnancies. Placental samples were taken from
normal pregnancies (n = 9), and pregnancies complicated with GDM
where glucose levels were managed with diet (n = 7) or metformin (n =
6). (a) Representative western blots of occludin isoform-A (~60 kDa) and
isoform-B (~ 30 kDa) from placental samples from normal (N), d-GDM
(D), and m-GDM (M) pregnancies. β-Actin (~40 kDa) was used as a
loading control. (b, c) Graphs of relative expression of occludin
isoform-A (b) and occludin isoform-B (c) in samples from the three
groups. Data are presented as mean ± SEM; missing data correspond to
outliers. *p < 0.05 by post hoc unpaired t test
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leakage [12]. The altered expression of occludin isoforms seen
in placentas from the d-GDM study group suggests that there
is an additional mechanism at play.
Our study reports the expression of two occludin protein
isoforms (occludin isoform-A and occludin isoform-B) in
human placental vessels. As stated above, occludin isoform-
A is a fully functional protein that oversees the stability of the
membrane [34]; a decrease of this may affect junctional
integrity. This hypothesis was confirmed by the 29% decrease
seen in d-GDM samples, decreased percentage of occludin-
positive vessels and increased vascular leakage in conduit
vessels. Protein expression of occludin isoform-A was not
altered in the m-GDM group vs the normal group.
Curiously, the protein expression of occludin isoform-B, a
truncated protein implicated in preventing claudin-4 from






















Fig. 6 Increased tracer leakage in




channel) and dextran tracer
(TRITC channel) from perfused
placentas from normal
pregnancies (n = 4), and d-GDM
pregnancies (n = 4). (a, b) Fetal
vessels in stem villi (sv) and
intermediate villi (iv) from
normal pregnancies showing no
or discreet (<2 hotspots) leakage
of 75Mr TRITC-dextran. (c–e) In
placentas from the d-GDM group,
hotspots of tracer (red) can be
seen trapped in the interstitium
adjacent to vascular profiles in
intermediate and stem villi. (e) A
composite of the micrographs in
(c) and (d) highlighting hotspots.
Scale bar, 50 μm. (f) Comparison
of percentage of conduit vessels
with peri-vascular hotspots
between the two groups. Data are
presented as mean ± SEM.












































































































Fig. 7 Higher miR-181a-5p expression in d-GDM placental samples.
Placental samples were taken from normal pregnancies (n = 9), and preg-
nancies complicated with d-GDM (n = 7) or metformin (n = 6). The
expression of miR-18a-5p (a), miR-21-3p (b) and miR-181a-5p (c) in
the three groups. Data are presented as mean ± SEM. *p < 0.05 by post
hoc unpaired t test
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permeability [19], was similar among the three groups.
Whether this isoform can hamper the barrier integrity function
of occludin isoform-A in the placenta requires investigation.
The presence of two occludin protein isoforms suggested
that the OCLN gene is regulated by alternative splicing. Our
previous study confirmed, for the first time, the expression of
three OCLN splice variants (OCLN variant 1, variant 2 and
variant 3) in human placental tissue [35]. OCLN variant 2
represents ~67% of total OCLN expression in placental
samples from normal pregnancies. This variant and OCLN
variant 1 are responsible for the translation of occludin
isoform-A. We found that OCLN variant 2 expression was
decreased by 33% in d-GDM samples. This indicates that
the reduction in endothelial junctional occludin from d-
GDM samples is not only due to lower protein expression
but also the result of a downregulation of OCLN variant 2
expression. OCLN variant 3 represents ~18% of total OCLN
expression in normal pregnancy samples, and is translated into
occludin isoform-B. Contrary to our results for isoform-B
protein expression, in placental samples from the d-GDM
groupOCLN variant 3 expression was 3.3-fold that in samples
from normal pregnancies. Therefore, there is still the possibil-
ity that the translation of OCLN variant 3 may be
compromised.
The significant differences in the expression ofOCLN vari-
ant 2 and isoform-A in placentas from the d-GDM group
correlate with functional consequences. Perfusion of placental
microvascular beds in d-GDM revealed a 100% increase in
vessels associated with leaks of a 76Mr tracer (slightly larger
than albumin) compared with the physiological basal level of
leakage exhibited by the vessels in placental samples from the
normal pregnancy group (Fig. 6). In the placenta, paracellular
permeability to hydrophilic solutes can be induced by VEGF
and histamine. We previously reported that perfusion with




















































































































































Fig. 8 Overexpression of miR-
181a-5p downregulates OCLN
expression. HUVECs isolated
from normal pregnancies (n = 4)
were subject to four transfection
conditions for 48 h: untreated
control (UC), transfection control
(TC), negative control (NC), and
miR-181a-5p transfection (miR).
(a) miR-181a-5p expression in
HUVECs transfected with the
mimic. (b–d) Expression of
OCLN variant 1 (b), OCLN
variant 2 (c) and OCLN variant 3
(d). Data are presented as mean ±
SEM of four independent
experiments, each condition
performed in triplicate. *p < 0.05,
**p < 0.01, ***p < 0.001 post hoc
unpaired t test
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Fig. 9 Overexpression of miR-181a-5p reduces endothelial barrier integ-
rity and increases permeability. HUVECs isolated from normal pregnan-
cies (n = 4) were subject to four transfection conditions: untreated control
(UC), transfection control (TC), negative control (NC) and miR-181a-5p
transfection (miR). (a) TEER was measured every 24 h after transfection
(t0) for 72 h. (b) Tracer leakage wasmeasured 48 h after transfection. Data
are presented as mean ± SEM of four independent experiments, each
condition performed in triplicate. *p < 0.05, ***p < 0.001 by post hoc
unpaired t test
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VEGF-A resulted in reversible TRITC-labelled 76Mr dextran
leaks and loss of junctional adhesion molecules throughout
the placental vascular tree [12], while histamine significantly
increased the separation between adjoining endothelial
membrane leaflets at tight junction regions (4.1–6.1 nm) but
not at adherens junctional zones, leading to increased trans-
port of the smaller molecules cyanocobalamin and EDTA, but
not albumin [10]. In the present study, the d-GDM perfused
placental leakage pattern suggests the influence of inflamma-
tory conditions and altered structural composition of tight
junctions induced by the reduced expression of the transmem-
brane isoform of occludin. The perfused placentas from the d-
GDM group showing altered vascular leaks have not been
interrogated with anti-occludin antibodies. The assumption
here was that they would have a loss of occludin similar to
that observed in the immunofluorescence studies of vascular
profiles of the d-GDM study group. Nevertheless, the subop-
timal functioning of the d-GDM placental endothelial barrier,
i.e. the increased number of conduit vessels showing
perivascular tracer hotspots, albeit mild, may have a detrimen-
tal effect on total placental function and, concurrently, the
developing fetus whose vasculature is in continuum with the
placental vasculature. GDM occurs late in gestation, from
second trimester onwards, but this shorter exposure to the
diabetic milieu still resulted in increased vascular leakage
and changes in occludin expression.
Birthweight centiles revealed that some babies were LGA
in both the normal and GDM groups. However, no correla-
tions were found between birthweight centiles and occludin
protein, gene expression or vascular leakage. Complex inter-
actions of fetal hyperinsulinaemia, hypoxia and overnutrition
are involved in the development fetal macrosomia and
assessment of measures of these factors was beyond the scope
of this study.
Given that OCLN expression was affected in the d-GDM
group, we explored epigenetic control. Screening for miRNAs
that target OCLN, revealed that miR-18a-5p, miR-21-3p and
miR-181a-5p are expressed in human placenta. The expres-
sion of miR-18a-5p and miR-21-3p was similar among
groups. However, expression of miR-181a-5p was higher in
placental samples from d-GDM pregnancies compared with
those from normal pregnancies. Overexpression of miR-181a-
5p in HUVECs resulted in an impaired endothelial barrier
(78% reduction in resistance), increased 76Mr dextran perme-
ability (1.3-fold), as well as the decrease in gene expression of
OCLN variants 1 and 2. TEER is considered a better in vitro
marker of tight junctional integrity in endothelial monolayers
with discontinuous ‘kissing’ tight junctions, whilst permeabil-
ity and transit time of molecules slightly larger than albumin
reflect changes in wide zone composition and frequency of
tight junctional strand discontinuities along the paracellular
cleft [11]. Studies with human glioma endothelial cells
showed that overexpression of miR-181a-5p reduces endothe-
lial resistance and the gene expression of tight junction mole-
cules OCLN, ZO-1 and CLDN-5 [36]. Higher expression of
miR-181a was found in non-pregnant individuals with type 1
and type 2 diabetes [37–39] and women affected by a GDM
pregnancy tested after 3–11 years [40]. There is evidence that
placental miRNAs can traffic to the maternal and fetal circu-
lation [41, 42], thus the possibility remains that the higher
expression of miR-181a-5p observed in the d-GDM group
could affect maternal and fetal tight junctions. Increased pres-
ence of miR-181a-5p in the circulation could lead to down-



































































Fig. 10 Reduced VEGF-A protein expression in human placental tissue
from d-GDM pregnancies. Placental samples were taken from normal
pregnancies (n = 9), and pregnancies complicated with d-GDM (n = 7)
or m-GDM (n = 6). VEGF-A protein (a) and gene expression (b) were
analysed between groups. (c) Representative western blot bands of
VEGF-A (~45 kDa) from normal, diet-controlled and metformin-
controlled placental samples.β-actin (~40 kDa) used as a loading control.
Data are presented as mean ± SEM. *p < 0.05 by post hoc unpaired t test
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diabetic retinopathy or nephropathy. The miRNA miR-181a-
5p could be one of the factors responsible for the downregu-
lation of occludin in d-GDM placental samples.
Metformin can cross the placenta and has been found in the
fetal circulation [43]. It is used for different clinical conditions
and reduces insulin resistance. A study using metformin treat-
ment for GDM showed that insulin resistance decreased in
blood samples at term compared with baseline [44]. The use
of metformin in women with polycystic ovary syndrome
(PCO) before conception and during pregnancy reduced
serum insulin, insulin resistance and insulin secretion [45].
Several studies have focused on the outcome of offspring from
pregnancies treated with metformin. These found no apparent
reason for concern on short-term [46–48], or long-term,
effects of fetal exposure to metformin [49–51]. In our study,
there were no differences in neonatal weight between normal
and m-GDM pregnancies; however, the gestational age of the
latter was >39 weeks. We did find that m-GDM placentas
presented stable expression of occludin gene and protein
levels. These results suggest a regulatory effect of metformin
over occludin expression in GDM pregnancies but further
investigation is required to determine the underlying
mechanism.
In conclusion, feto-placental vessels from pregnancies
complicated with d-GDM allow the extravasation of normally
restricted macromolecules. Beyond phosphorylation of junc-
tional molecules, loss of junctional occludin may be, in part,
due to the downregulation of occludin expression and
decreased localisation to tight junctions, altered splicing and
elevated miR-181a-5p expression. These effects were only
visible in the d-GDM group; treatment with metformin
appeared to normalise the effects. Our study suggests that
lifestyle changes (diet and exercise) in GDM may not be
enough to prevent alterations in the expression of occludin
and the endothelial barrier integrity. Moreover, these placental
changes may be reflecting impaired vascular barrier function
in the offspring and their increased vulnerability to inflamma-
tory insults.
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